Development & Characterization of Solid Lipid Nanoparticles of Lasmiditan

The present study focuses on the development and characterization of solid lipid nanoparticles (SLNs) of Lasmiditan with the aim of enhancing drug encapsulation, stability, and controlled drug release. Solid lipid nanoparticles were formulated using lipid-based excipients due to their biocompatibility, biodegradability, and ability to improve the bioavailability of poorly soluble drugs. Lasmiditan-loaded SLNs were prepared by the solvent evaporation method, employing stearic acid as the solid lipid, Tween 20 as the surfactant, and propylene glycol as the co-surfactant. Preformulation studies confirmed the suitability of Lasmiditan for incorporation into lipid matrices, and UV spectrophotometric analysis established its maximum absorbance at 255 nm in phosphate buffer pH 7.4 for analytical evaluation. Among all formulations, LSLN7 exhibited the smallest particle size, highest entrapment efficiency, and satisfactory zeta potential, indicating good colloidal stability. Surface morphological studies using scanning electron microscopy revealed nanosized particles with some aggregation attributed to the freeze-drying process. In vitro drug release studies demonstrated sustained release behavior, with the optimized formulation LSLN7 showing 99.01% drug release over 12 hours. Release kinetics analysis suggested diffusion-controlled drug release. Stability studies indicated no significant changes in physical appearance, particle size, or entrapment efficiency under different storage conditions. Overall, the results demonstrate that Lasmiditan-loaded solid lipid nanoparticles, particularly formulation LSLN7, represent a promising and stable drug delivery system suitable for further in vivo evaluation.